- search hit 1 of 1
Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience
Please always quote using this URN: urn:nbn:de:bvb:20-opus-147407
- Tyrosine kinase inhibitors (TKI) have shown clinical effectiveness in iodine-refractory differentiated thyroid cancer (DTC). The corresponding role of serum thyroglobulin (Tg) in iodine-refractory DTC has not been investigated yet. 9 patients (3 female, 61 ± 8y) with progressive iodine-refractory DTC starting on lenvatinib were considered. Tumor restaging was performed every 2–3 months including contrast-enhanced computed tomography (CT, RECIST 1.1). Serum Tg was measured and compared to imaging findings. After treatment initiation, serum TgTyrosine kinase inhibitors (TKI) have shown clinical effectiveness in iodine-refractory differentiated thyroid cancer (DTC). The corresponding role of serum thyroglobulin (Tg) in iodine-refractory DTC has not been investigated yet. 9 patients (3 female, 61 ± 8y) with progressive iodine-refractory DTC starting on lenvatinib were considered. Tumor restaging was performed every 2–3 months including contrast-enhanced computed tomography (CT, RECIST 1.1). Serum Tg was measured and compared to imaging findings. After treatment initiation, serum Tg levels dropped in all patients with a median reduction of 86.2%. During long-term follow-up (median, 25.2 months), fluctuations in Tg could be observed in 8/9 subjects. According to RECIST, 6/9 subjects achieved a partial response or stable disease with the remaining 3/9 experiencing progressive disease (2/3 with Tg levels rising above baseline). All of the patients with disease progression presented with a preceding continuous rise in serum Tg, whereas tumor marker oscillations in the subjects with controlled disease were only intermittent. Initiation of lenvatinib in iodine-refractory DTC patients is associated with a significant reduction in serum Tg levels as a marker of treatment response. In the course of treatment, transient Tg oscillations are a frequent phenomenon that may not necessarily reflect morphologic tumor progression.…
Author: | R. A. Werner, K. Lückerath, J. S. Schmid, T. Higuchi, M. C. Kreissl, I. Grelle, C. Reiners, A. K. Buck, C. Lapa |
---|---|
URN: | urn:nbn:de:bvb:20-opus-147407 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Language: | English |
Parent Title (English): | Scientific Reports |
Year of Completion: | 2016 |
Volume: | 6 |
Pagenumber: | 28081 |
Source: | Scientific Reports 6, 28081; doi: 10.1038/ srep28081 (2016) |
DOI: | https://doi.org/10.1038/srep28081 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten |
Tag: | Thyroid cancer |
Release Date: | 2017/05/17 |
Collections: | Open-Access-Publikationsfonds / Förderzeitraum 2016 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung |